So A - Search Results

1

Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum.

Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, O'Neil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C. Nappi L, et al. Among authors: so a. J Clin Oncol. 2019 Nov 20;37(33):3090-3098. doi: 10.1200/JCO.18.02057. Epub 2019 Sep 25. J Clin Oncol. 2019. PMID: 31553692 Free PMC article.

2

Androgens and prostate cancer.

So AI, Hurtado-Coll A, Gleave ME. So AI, et al. World J Urol. 2003 Nov;21(5):325-37. doi: 10.1007/s00345-003-0373-9. Epub 2003 Oct 29. World J Urol. 2003. PMID: 14586548 Review.

3

Prostate specific antigen: an updated review.

So A, Goldenberg L, Gleave ME. So A, et al. Can J Urol. 2003 Dec;10(6):2040-50. Can J Urol. 2003. PMID: 14704108 Review.

4

Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME. July LV, et al. Among authors: so a. Mol Cancer Ther. 2004 Mar;3(3):223-32. Mol Cancer Ther. 2004. PMID: 15026542

5

Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.

So AI, Bowden M, Gleave M. So AI, et al. BJU Int. 2004 Apr;93(6):845-50. doi: 10.1111/j.1464-410X.2003.04726.x. BJU Int. 2004. PMID: 15050003

6

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Rocchi P, et al. Among authors: so a. Cancer Res. 2004 Sep 15;64(18):6595-602. doi: 10.1158/0008-5472.CAN-03-3998. Cancer Res. 2004. PMID: 15374973

7

Mechanisms of the development of androgen independence in prostate cancer.

So A, Gleave M, Hurtado-Col A, Nelson C. So A, et al. World J Urol. 2005 Feb;23(1):1-9. doi: 10.1007/s00345-004-0473-1. Epub 2005 Jan 27. World J Urol. 2005. PMID: 15770516 Review.

8

Antisense oligonucleotide therapy in the management of bladder cancer.

So A, Rocchi P, Gleave M. So A, et al. Curr Opin Urol. 2005 Sep;15(5):320-7. doi: 10.1097/01.mou.0000175572.46986.2c. Curr Opin Urol. 2005. PMID: 16093856 Review.

9

Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.

So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. So A, et al. Mol Cancer Ther. 2005 Dec;4(12):1837-49. doi: 10.1158/1535-7163.MCT-05-0178. Mol Cancer Ther. 2005. PMID: 16373699

10

Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.

Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, Gleave ME. Yamanaka K, et al. Among authors: so a. BJU Int. 2006 Jun;97(6):1300-8. doi: 10.1111/j.1464-410X.2006.06147.x. BJU Int. 2006. PMID: 16686729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

799 results

Search Page

Filters